Insider Buying: Kenneth J. Zuerblis Acquires 1,000 Shares of Stemline Therapeutics Stock (STML)
Stemline Therapeutics (NASDAQ:STML) Director Kenneth J. Zuerblis purchased 1,000 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The stock was purchased at an average price of $11.14 per share, with a total value of $11,140.00. Following the completion of the transaction, the director now directly owns 11,963 shares of the company’s stock, valued at approximately $133,268. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Stemline Therapeutics (NASDAQ:STML) opened at 10.85 on Friday. Stemline Therapeutics has a 52 week low of $10.509 and a 52 week high of $47.25. The stock has a 50-day moving average of $11.56 and a 200-day moving average of $16.32. The company’s market cap is $140.5 million.
Stemline Therapeutics (NASDAQ:STML) last released its earnings data on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.24.
Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.